| Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
| New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
| Chimerix (CMRX) | Morgan Stanley/ Cowen and Company | $85.00 | n.a. | |||
| n.a. (not available) | ||||||
| Postponed | ||||||
| None | ||||||
| Withdrawn | ||||||
| None | ||||||
| New Terms | ||||||
| Cancer Genetics (CGIX) | Aegis Capital/ Feltl and Company | 1.85 | $10.00 | $12.00 | $20.35 | 1-Star |
| Enanta Pharmaceuticals (ENTA) | J.P. Morgan/ Credit Suisse | 4.00 | $14.00 | $16.00 | $60.00 | 2-Stars |
| Model N (MODN) | J.P. Morgan/ Deutsche Bank Securities | 6.46 | $12.50 | $14.50 | $87.21 | 2-Stars |
| Tetraphase Pharmaceuticals (TTPH) | Barclays/ BMO Capital Markets | 6.82 | $10.00 | $12.00 | $75.00 | 1-Star |
| IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
| Week of March 4, 2013 | Manager(s) | Offered | Raised | Price | 3/8/13 | Change |
| Artisan Partners Asset Management (APAM) | Citigroup/ Goldman, Sachs | 11.05 | $331.62 | $30.00 | $38.65 | 28.83% |
| Professional Diversity Network (IPDN) | Aegis Capital | 2.63 | $21.00 | $8.00 | $7.19 | -10.13% |
